Shopping Cart
Remove All
Your shopping cart is currently empty
AurAP14
Catalog No. T215239 Copy Product Info
🥰Excellent
AurAP14 is an Aurora APROTAC degrader with a DC50 of 120 nM. It exhibits notable inhibitory activity against various tumor cell lines, with an IC50 of 0.294 μM in A549 cells and 0.534 μM in MCF-7 cells. AurAP14 induces apoptosis in A549 cells and causes cell cycle arrest in the S and G2/M phases. It demonstrates antitumor efficacy in both A549 and A549/PTR nude mouse xenograft models. AurAP14 is applicable for studying treatments for non-small cell lung cancer (NSCLC) with Aurora A overexpression.
AurAP14
Copy Product Info🥰Excellent
Catalog No. T215239
AurAP14 is an Aurora APROTAC degrader with a DC50 of 120 nM. It exhibits notable inhibitory activity against various tumor cell lines, with an IC50 of 0.294 μM in A549 cells and 0.534 μM in MCF-7 cells. AurAP14 induces apoptosis in A549 cells and causes cell cycle arrest in the S and G2/M phases. It demonstrates antitumor efficacy in both A549 and A549/PTR nude mouse xenograft models. AurAP14 is applicable for studying treatments for non-small cell lung cancer (NSCLC) with Aurora A overexpression.
AurAP14
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | AurAP14 is an Aurora APROTAC degrader with a DC50 of 120 nM. It exhibits notable inhibitory activity against various tumor cell lines, with an IC50 of 0.294 μM in A549 cells and 0.534 μM in MCF-7 cells. AurAP14 induces apoptosis in A549 cells and causes cell cycle arrest in the S and G2/M phases. It demonstrates antitumor efficacy in both A549 and A549/PTR nude mouse xenograft models. AurAP14 is applicable for studying treatments for non-small cell lung cancer (NSCLC) with Aurora A overexpression. |
| Targets&IC50 | Aurora A:120 nM (DC50) |
| In vitro | AurAP14, in concentrations ranging from 0.1 to 4 μM, degrades Aurora A, inhibits Aurora A-mediated phosphorylation of p53 (Ser315), and disrupts the non-catalytic protection of the proto-oncogene protein C-MYC in MCF-7 and A549 cells. At a concentration of 0.5 μM over 24 hours, AurAP14 hinders migration and colony formation of A549 cells, causing cell cycle arrest in the S and G2/M phases. Additionally, AurAP14 at 0.5 μM for 24 to 48 hours induces apoptosis in A549 cells. |
| In vivo | AurAP14 (administered intraperitoneally at 30 mg/kg every 2 days for 21 days) effectively inhibits tumor growth in A549 and A549/PTR nude mouse xenograft models. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy AurAP14 | purchase AurAP14 | AurAP14 cost | order AurAP14 | AurAP14 in vivo | AurAP14 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.